|
Logo placeholder
|
| Location |
Boston, MA, USA |
| Type |
Academic Medical Center |
| Affiliation |
Harvard Medical School |
| Founded |
1811 |
| Website |
massgeneral.org |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, ALS, FTD, HD |
Massachusetts General Hospital is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Massachusetts General Hospital (MGH) is the original and largest teaching hospital of Harvard Medical School, founded in 1811. Located in Boston, Massachusetts, MGH is consistently ranked among the top hospitals in the United States and is a global leader in medical research and patient care. The hospital's Department of Neurology and the Mass General Institute for NeuroDiscovery conduct pioneering research across all neurodegenerative diseases.
MGH was founded in 1811 and has been at the forefront of medical innovation for over two centuries:
- 1811: Founded as the first teaching hospital of Harvard Medical School
- 1846: First public demonstration of anesthesia in the United States
- 1936: Established one of the first dedicated neurology departments in the nation
- 1990s: Launched the Center for Neurodegeneration Research
- 2000s: Founded the Mass General Institute for NeuroDiscovery
MGH maintains comprehensive research programs:
- Amyloid and Tau Research: Basic and translational studies on protein aggregation
- Neuroimaging: PET and MRI research for early detection and monitoring
- Clinical Trials: Leading Phase I-III trials for novel therapeutics
- Biomarker Development: CSF, blood, and imaging biomarkers
¶ Parkinson's Disease and Movement Disorders
Research programs include:
- Alpha-synuclein biology and propagation mechanisms
- LRRK2, GBA, and other genetic risk factors
- Deep brain stimulation outcomes research
- Clinical trials for disease-modifying therapies
¶ ALS and Motor Neuron Disease
MGH researchers investigate:
- SOD1, C9orf72, FUS, and TARDBP genetics and biology
- TDP-43 proteinopathy mechanisms
- Novel therapeutic approaches and biomarkers
Research programs focus on:
- Mutant huntingtin aggregation and toxicity
- Genetic modifiers and disease progression
- Clinical trials for disease-modifying therapies
Programs investigate:
- Tau and TDP-43 pathology
- GRN, MAPT, and C9orf72 genetic forms
- Clinical phenotype characterization
Founded in 2005, the Institute coordinates all neurodegeneration research at MGH, bringing together over 100 researchers across multiple departments.
The MGH Department of Neurology is one of the largest in the nation, with over 200 faculty members conducting research across all neurological disorders.
This center focuses on the molecular and cellular mechanisms of neurodegeneration, with an emphasis on translating discoveries into new therapies.
MGH is home to world-renowned neuroscientists:
- Dr. John Hardy's group - Pioneering work on APP and tau genetics
- Dr. Bradley Hyman - Leader in Alzheimer's disease research
- Dr. Merit Cudkowicz - Chief of Neurology, ALS researcher
- Dr. Bruce Rosen - Director of Martinos Center for Biomedical Imaging
MGH operates specialty clinics:
- Memory Disorders Unit
- Movement Disorders Unit
- ALS Clinic
- Huntington's Disease Unit
- Frontotemporal Dementia Program
MGH offers extensive training opportunities:
- Neurology residency program
- Fellowships in movement disorders, memory disorders, ALS
- Postdoctoral research fellowships
- Graduate student rotations
MGH maintains global research partnerships:
- Harvard Medical School affiliates
- University of Cambridge
- UCL Institute of Neurology
- Karolinska Institutet
- Global Alzheimer's Association
The study of Massachusetts General Hospital has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hardy J, et al. (2018). The amyloid hypothesis of Alzheimer's disease: 25 years later. EMBO Molecular Medicine. 10(7):e9427. PMID:29915016
- Hyman BT, et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & Dementia. 8(1):1-13. PMID:22265587
- Cudkowicz ME, et al. (2014). Towards an efficient treatment for ALS. Annals of Neurology. 76(2):161-163. PMID:25088045
- Ross CA, et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 10(4):204-216. PMID:24610614
- Rascovsky K, et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 134(Pt 9):2456-2477. PMID:21810890
- Spillantini MG, et al. (1997). Alpha-synuclein in Lewy bodies. Nature. 388(6645):839-840. PMID:9278044
- Polymeropoulos MH, et al. (1997). Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 274(5295):1197-1199. PMID:9177569
- Rosen MR, et al. (2013). The future of brain imaging in neurology. JAMA Neurology. 70(10):1235-1241. PMID:23942609